Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|November 20, 2019

West Introduces Two Elastomer Products at CPhI Worldwide 2019

The company introduced its new advanced elastomer, the 4040/40 formulation, and a new line extension of its AccelTRA component program, AccelTRA Select, at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.

West Pharmaceutical Services, an injectable drug administration company based in Exton, PA, introduced its new advanced elastomer, the 4040/40 formulation, and a new line extension of its AccelTRA component program, AccelTRA Select, at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.

According to a Nov. 5, 2019 company press release, the 4040/40 formulation is available in two 13-mm and 20-mm LyoTec stopper designs for reliability and high functionality. The new device also includes Westar Select quality and low particulate levels, with a design, drug compatibility, and quality to protect drug stability, drive performance, and reduce fill-finish rejects.

Additionally, the AccelTRA Select comes equipped with AccelTRA 13-mm and 20-mm serums and lyo stoppers in numerous configurations, along with a 1–3-mL uncoated plunger, according to the release. The program also utilizes the Westar Select wash process to provide high-quality options for generic drug manufacturers.

“These new elastomer product offerings reflect West’s deep commitment to innovation based on customer insights. Designed with the customers’ challenges in mind, we aim to simplify their journey with drug packaging and delivery solutions and help bring much-needed injectable medicines to patients more quickly and efficiently,” said Karen Flynn, senior vice-president and chief commercial officer, West, in the press release. “CPhI also marks our first full year offering the Integrated Solutions program, our comprehensive approach to working by our customers’ side to help reduce risk and regulatory complexity. Together with these new product offerings, West supports customers as they navigate the journey from early development to commercialization.”

Source: West Pharmaceutical Services

 

 

Related to this article

View more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more